Free Trial
NASDAQ:KURA

Kura Oncology 9/18/2023 Earnings Report

Kura Oncology logo
$5.54 -0.42 (-7.05%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$5.54 0.00 (0.00%)
As of 08/8/2025 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kura Oncology EPS Results

Actual EPS
-$68.25
Consensus EPS
-$6.30
Beat/Miss
Missed by -$61.95
One Year Ago EPS
N/A

Kura Oncology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kura Oncology Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Kura Oncology Earnings Headlines

Kura (KURA) Revenue Drops 61%
Kura Oncology Reports Second Quarter 2025 Financial Results
Trump set to Boost Social Security Checks by 400%?
If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative...
See More Kura Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kura Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kura Oncology and other key companies, straight to your email.

About Kura Oncology

Kura Oncology (NASDAQ:KURA), a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

View Kura Oncology Profile

More Earnings Resources from MarketBeat